advisorsecurities master

ACETAdicet Bio, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key
11226
Ticker
ACET
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2020-09-16
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
ACET

Detail

Enriched 2026-08-14 20:47

Market cap
$77,325,907.4
Shares outstanding (class)
9,361,490
Shares outstanding (weighted)
9,361,490
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
102
Location
BOSTON, MA
Description

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data